Company Overview
Snapshot
Founded in July 2024 by Tom Shani, Avital Sharir-Ivry, and Amitai Mordechai, ProPhet operates with 1-10 employees. The company has secured funding across one round from four investors. In July 2024, ProPhet launched as a new AI startup from AION Labs, aiming to accelerate the identification of active small molecules for drug discovery.
Business overview
ProPhet is an AI-driven company focused on transforming small molecule drug discovery, particularly for proteins that are challenging to target using conventional methods. The company develops advanced technology leveraging artificial intelligence and machine learning to identify potential therapeutics. ProPhet's platform predicts protein dynamics and interactions with drug candidates, enabling rapid identification of promising molecules and opening new avenues for treating previously "undruggable" diseases. It serves the pharmaceutical and biotechnology industries by offering faster, more efficient, and cost-effective solutions for drug development.
Strategic signal
In October 2024, ProPhet was highlighted as a new Israeli startup utilizing AI to significantly reduce the time and cost associated with drug molecule discovery. This signals a strong market validation for its innovative approach to drug development, particularly its focus on difficult-to-treat proteins, positioning the company for rapid advancement in the pharmaceutical industry.
Log in to access full profile ›Company Intelligence Q&A
- When was ProPhet founded and by whom?
- ProPhet was founded in July 2024 by Tom Shani, Avital Sharir-Ivry, and Amitai Mordechai.
- What is ProPhet's core technology?
- ProPhet leverages artificial intelligence and machine learning to develop novel algorithms for evaluating protein conformational states and screening small molecule libraries, accelerating drug discovery.
- Which organizations partnered with ProPhet at its launch?
- In October 2024, ProPhet was launched by AION Labs, a venture studio backed by major pharmaceutical companies including AstraZeneca and Merck.
- What is ProPhet's primary focus in drug discovery?
- ProPhet focuses on transforming small molecule drug discovery, particularly targeting proteins that are difficult to address with competitive methods, aiming to identify potential therapeutics for these challenging targets.
- What is the strategic importance of ProPhet's launch from AION Labs?
- The launch of ProPhet from AION Labs in October 2024 signifies a strategic validation of its AI-driven approach to drug discovery, providing the startup with resources and industry connections to succeed in the pharmaceutical sector.